...ApS, a Danish start-up developing a Group B Streptococcus vaccine; publicly traded women’s health company Evofem Biosciences Inc....

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....

...Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc $58.1 Theravance Biopharma Inc. (NASDAQ:TBPH) $55.0 Evofem Biosciences Inc....

...GIST) Phase III data Mid-2019 Epizyme Inc. (NASDAQ:EPZM) Tazemetostat Treat epithelioid sarcoma Submit NDA 2Q19 Evofem Biosciences Inc....

...cohorts in the Phase III AMP001 trial to prevent pregnancy, despite meeting its primary endpoint. Evofem...
...18-35 and evaluated the cumulative pregnancy rate over seven 21-35 day cycles of Amphora use. Evofem Biosciences Inc....
...pregnancy rate over seven 21-35 day cycles Status: Phase III data Milestone: Resubmit NDA (2Q19) Sandi Wong Amphora Evofem Biosciences Inc. Contraception...

...and transition to a part-time role as executive medical director. Lynch also is chairman of Evofem...

...gel vs. a hydroxyethylcellulose placebo gel or no treatment in about 100 healthy female volunteers. Evofem...